Efficacy of β-lactam/β-lactamase inhibitors to treat extended-spectrum beta-lactamase-producing Enterobacterales bacteremia secondary to urinary tract infection in kidney transplant recipients (INCREMENT-SOT Project).
Ligia Camera Camera PierrottiElena Perez-NadalesMario Fernández-RuizBelén Gutiérrez-GutiérrezBan Hock TanJordi CarratalàIsabel OriolMical PaulNoa Cohen-SinaiFrancisco López-MedranoRafael San-JuanMiguel MontejoMaristela Pinnheiro FreireElisa CorderoMiruna D DavidEsperanza MerinoSeema Mehta SteinkePaolo Antonio GrossiÁngela CanoElena M SeminariMaricela ValerioFiliz GunserenMeenakshi RanaAlessandra MularoniPilar Martin-DavilaChristian van DeldenMelike Hamiyet DemirkayaZeliha Koçak TufanBelén LoechesRanganathan N IyerFabio SoldaniBritt-Marie ErikssonBenoît PilmisMarco RizziJulien CoussementWanessa T ClementeEmmanuel RoilidesAlvaro PascualLuis Martinez-MartinezJesús Rodríguez-BañoJulian Torre-CisnerosJose María Aguadonull nullPublished in: Transplant infectious disease : an official journal of the Transplantation Society (2021)
Our data suggest that active therapy based on BLBLI may be as effective as carbapenem-containing regimens for ESBL-E BSI secondary to UTI in the specific population of KTR. Potential residual confounding and unpowered sample size cannot be excluded (ClinicalTrials.gov identifier: NCT02852902).